Garnsey M, Wang Y, Edmonds D, Sammons M, Reidich B, Ahn Y
Nat Commun. 2025; 16(1):297.
PMID: 39746932
PMC: 11697577.
DOI: 10.1038/s41467-024-54487-5.
Demirtas C, Yilmaz Y
J Clin Transl Hepatol. 2024; 12(10):857-864.
PMID: 39440221
PMC: 11491501.
DOI: 10.14218/JCTH.2024.00257.
Wattacheril J, Kleinstein S, Shea P, Wilson L, Subramanian G, Myers R
medRxiv. 2024; .
PMID: 38496563
PMC: 10942529.
DOI: 10.1101/2024.03.02.24303632.
Smagris E, Shihanian L, Mintah I, Bigdelou P, Livson Y, Brown H
PLoS Genet. 2024; 20(3):e1011179.
PMID: 38437227
PMC: 10939284.
DOI: 10.1371/journal.pgen.1011179.
Kozlitina J, Cohen N, Sturtevant D, Cohen J, Murphey-Half C, Saltarrelli J
EClinicalMedicine. 2024; 67:102350.
PMID: 38169797
PMC: 10758751.
DOI: 10.1016/j.eclinm.2023.102350.
Structural basis of lipid-droplet localization of 17-beta-hydroxysteroid dehydrogenase 13.
Liu S, Sommese R, Nedoma N, Stevens L, Dutra J, Zhang L
Nat Commun. 2023; 14(1):5158.
PMID: 37620305
PMC: 10449848.
DOI: 10.1038/s41467-023-40766-0.
Dual targeting of hepatocyte DGAT2 and stellate cell FASN alleviates nonalcoholic steatohepatitis in mice.
Yenilmez B, Harney S, DiMarzio C, Kelly M, Min K, Echeverria D
bioRxiv. 2023; .
PMID: 37461560
PMC: 10350091.
DOI: 10.1101/2023.07.05.547848.
Race and Ethnicity in Non-Alcoholic Fatty Liver Disease (NAFLD): A Narrative Review.
Riazi K, Swain M, Congly S, Kaplan G, Shaheen A
Nutrients. 2022; 14(21).
PMID: 36364818
PMC: 9658200.
DOI: 10.3390/nu14214556.
Review article: the role of HSD17B13 on global epidemiology, natural history, pathogenesis and treatment of NAFLD.
Amangurbanova M, Huang D, Loomba R
Aliment Pharmacol Ther. 2022; 57(1):37-51.
PMID: 36349732
PMC: 10047549.
DOI: 10.1111/apt.17292.
Loss of immunity-related GTPase GM4951 leads to nonalcoholic fatty liver disease without obesity.
Zhang Z, Xun Y, Rong S, Yan L, Sorelle J, Li X
Nat Commun. 2022; 13(1):4136.
PMID: 35842425
PMC: 9288484.
DOI: 10.1038/s41467-022-31812-4.
Advances in pediatric non-alcoholic fatty liver disease: From genetics to lipidomics.
Riccio S, Melone R, Vitulano C, Guida P, Maddaluno I, Guarino S
World J Clin Pediatr. 2022; 11(3):221-238.
PMID: 35663007
PMC: 9134151.
DOI: 10.5409/wjcp.v11.i3.221.
Down-Regulating the High Level of 17-Beta-Hydroxysteroid Dehydrogenase 13 Plays a Therapeutic Role for Non-Alcoholic Fatty Liver Disease.
Wang M, Li J, Li H, Dong B, Jiang J, Liu N
Int J Mol Sci. 2022; 23(10).
PMID: 35628360
PMC: 9146021.
DOI: 10.3390/ijms23105544.
Contribution of a genetic risk score to ethnic differences in fatty liver disease.
Kubiliun M, Cohen J, Hobbs H, Kozlitina J
Liver Int. 2022; 42(10):2227-2236.
PMID: 35620859
PMC: 9427702.
DOI: 10.1111/liv.15322.
HSD17B13: A Potential Therapeutic Target for NAFLD.
Zhang H, Su W, Xu H, Zhang X, Guan Y
Front Mol Biosci. 2022; 8:824776.
PMID: 35071330
PMC: 8776652.
DOI: 10.3389/fmolb.2021.824776.
Genetics Is of the Essence to Face NAFLD.
Meroni M, Longo M, Tria G, Dongiovanni P
Biomedicines. 2021; 9(10).
PMID: 34680476
PMC: 8533437.
DOI: 10.3390/biomedicines9101359.
Metabolic drivers of non-alcoholic fatty liver disease.
Bence K, Birnbaum M
Mol Metab. 2020; 50:101143.
PMID: 33346069
PMC: 8324696.
DOI: 10.1016/j.molmet.2020.101143.
A closer look at the mysterious HSD17B13.
Dong X
J Lipid Res. 2020; 61(11):1361-1362.
PMID: 33008926
PMC: 7604724.
DOI: 10.1194/jlr.C120001160.
Characterization of essential domains in HSD17B13 for cellular localization and enzymatic activity.
Ma Y, Karki S, Brown P, Lin D, Podszun M, Zhou W
J Lipid Res. 2020; 61(11):1400-1409.
PMID: 32973038
PMC: 7604732.
DOI: 10.1194/jlr.RA120000907.
Validating a non-invasive, ALT-based non-alcoholic fatty liver phenotype in the million veteran program.
Serper M, Vujkovic M, Kaplan D, Carr R, Lee K, Shao Q
PLoS One. 2020; 15(8):e0237430.
PMID: 32841307
PMC: 7447043.
DOI: 10.1371/journal.pone.0237430.
17-Beta Hydroxysteroid Dehydrogenase 13 Deficiency Does Not Protect Mice From Obesogenic Diet Injury.
Ma Y, Brown P, Lin D, Ma J, Feng D, Belyaeva O
Hepatology. 2020; 73(5):1701-1716.
PMID: 32779242
PMC: 8627256.
DOI: 10.1002/hep.31517.
